drug
Radicava
Marketedupdated 6mo agoby $SGIOF SHIONOGI & CO LTD
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying Radicava
- phase2Safety and Efficacy of Edaravone Dexborneol Sublingual Tablets for Blood-Brain Barrier Dysfunction in CADASIL
- phase1Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects
- phase4Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
- phase2Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
- —Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
- phase3Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke
News(2)
- Shionogi makes $2B rare disease play with IntraBio buyWith its acquisition of IntraBio, Shionogi will gain ownership over Aqneursa, which could hit peak global sales of $1 billion across its two indications in Niemann-Pick disease type C and ataxia-te…biospace · 1mo ago
- Shionogi pays $2B to acquire a rare disease startupThe acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a marketed treatment for two inherited conditions.biopharma_dive · 1mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that